Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

Immunicum AB. (10/16/18). "Press Release: Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel - a New and Innovative Cancer Immunotherapy [Not for US, AU, CA, et al

Organisations Organisation Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)
  Organisation 2 Sweden (govt)
Products Product ilixadencel
  Product 2 investment banking
Index term Index term Immunicum–SEVERAL: investment, 201810– capital increase SEK351m with 40.3m new shares at SEK8.5/share
Persons Person de Sousa, Carlos (Immunicum 201610– CEO before Zealand Pharma + Nycomed/Takeda + Pfizer + Novartis + BBB Therapeutics)
  Person 2 Gertz, Michaela (Immunicum 201802– CFO before PledPharma AB + Accelerator Nordic AB + ITP Invest AB)

Record changed: 2018-10-24


Picture [iito] Plain Stupid Simple 650x80px

More documents for Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top